Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.36 |
| ▸ | RORB | Q92753 | 7/20 | 0.36 |
| ▸ | RORA | P35398 | 6/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13423945 | 0.90 | RORC (0.38) | RORCRORBRORANR1I2BRD4 | |
| SCHEMBL13423901 | 0.90 | BRD4 (0.36) | RORCRORBRORANR1I2BRD4 | |
| SCHEMBL13423959 | 0.88 | BRD4 (0.35) | RORCRORBRORANR1I2BRD4 | |
| SCHEMBL13423910 | 0.85 | RORC (0.39) | RORCRORBRORANR1I2PIK3C3 | |
| SCHEMBL13423958 | 0.82 | BRD4 (0.35) | RORCRORBRORANR1I2BRD4 | |
| SCHEMBL13424083 | 0.81 | CREBBP (0.34) | RORCRORBRORANR1I2BRD4 | |
| SCHEMBL13423925 | 0.81 | SRC (0.34) | PIK3CG | |
| SCHEMBL13423954 | 0.75 | NR1I2 (0.32) | RORCRORBRORANR1I2 | |
| SCHEMBL13424082 | 0.74 | CREBBP (0.36) | BRD4CREBBPPIK3C3SLC5A1 | |
| SCHEMBL13423947 | 0.74 | NR3C2 (0.35) | RORCRORBRORANR1I2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350084-B1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-8653097-B2 | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653097-B2 | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010043676-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | CCNK, CDK1, CDKN1A | RORC 1428/4885RORB 1552/4885RORA 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.